Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- CSIMC Subcommittee Approves Special Price Reductions for Combination Drugs
November 18, 2011
- CSIMC Excludes DPC Flat-Sum Reimbursement, Recommends Approval for Reimbursement by Piecework for 5 APIs
November 18, 2011
- Korosho Approves 3 Switch OTC Products Containing Pemirolast
November 18, 2011
- Similar Products to Be Re-Priced by Product Following Market Expansion: CSIMC Expert Subcommittee
November 17, 2011
- Industry Renews Call for Perpetual Introduction of Premium for New Drug Development: CSIMC Expert Subcommittee
November 17, 2011
- Re-pricing of Essential Drugs Discussed at CSIMC
November 17, 2011
- CSIMC Recommends Listing of 9 Products Including Imusera; Recommendation Put on Hold for Ilaris
November 17, 2011
- Plaintiffs to Appeal Against “Unprecedented Unjust Ruling”: Iressa Appeal Trial
November 17, 2011
- Subcommittee to Study “Notification System” for Access to Unapproved Drugs
November 17, 2011
- PM Noda Says “Japan Will Not Lose” Public Health Insurance System in TPP
November 16, 2011
- Health Minister Komiyama Says “Government Position Recognized” in Iressa Case
November 16, 2011
- DPJ’s Medical and Nursing Care WT Discuss Promotion of Generic Drugs
November 16, 2011
- High Court Turns Down Iressa Compensation Appeal
November 16, 2011
- 7-Drug Rule Should Be Relaxed or Eliminated to Promote GE Name Prescribing: Dr Adachi of CSIMC
November 16, 2011
- Mr Sawai of JGA Opposes Reduction in NHI Prices of First Generics
November 16, 2011
- PAFSC Committee Recommends Classification of Isoconazole as Class 1 OTC Drug
November 15, 2011
- Merck Withdraws MAA for Sitagliptin, Pioglitazone Combination
November 15, 2011
- Former Health Minister Masuzoe Raises Drug Re-Pricing Issues Over TPP
November 14, 2011
- 2007’s “Emergency Proposal” for Distribution Reform Needs Review: Health Ministry Councilor Mr Takeda
November 11, 2011
- Discontinuation of Vaccination Following Death due to Unknown Cause Cannot Be Considered: David Salisbury, UK Director for Vaccines and Immunization
November 11, 2011
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…